Advertisement
Gynecologic Oncology
Advanced searchSave search
Editorial| Volume 143, ISSUE 2, P227-228, November 2016

Download started.

Ok

STIC-ing with what we know

  • Lee-may Chen
    Correspondence
    Tel.: +1 415 885 7561; fax: +1 415 885 3586.
    Affiliations
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Science, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, 550 16th St. 7th Floor, San Francisco, CA 94158
    Search for articles by this author
DOI:https://doi.org/10.1016/j.ygyno.2016.10.007
STIC-ing with what we know
Previous ArticleEditorial Board
Next ArticleSGO Health Policy and Socioeconomic Committee: Current and Future Efforts of the Coding and Reimbursement Taskforce and the Policy, Quality and Outcomes Taskforce
      It is time to agree that serous tubal intraepithelial carcinomas (STIC lesions) are cancers, even though the management of occult STIC lesions, whether additional surgical staging or chemotherapy is indicated, remains unclear.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Zakhour M.
        • Danovitch Y.
        • Lester J.
        • et al.
        Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
        Gynecol. Oncol. 2016; 143: 231-235
        View in Article
        • Patrono M.G.
        • Iniesta M.D.
        • Malpica A.
        • et al.
        Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
        Gynecol. Oncol. 2015; 139 (PMID: 26407480): 568-572https://doi.org/10.1016/j.ygyno.2015.09.018
        View in Article
        • Conner J.R.
        • Meserve E.
        • Pizer E.
        • et al.
        Outcome of adnexal neoplasia discovered during risk reducing salpingo-oophrectomy in women with germ-lin BRCA1 or BRCA2 mutations.
        Gynecol. Oncol. 2014; 132: 280-286
        View in Article
        • Wethington S.L.
        • Park K.J.
        • Soslow R.A.
        • et al.
        Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).
        Int. J. Gynecol. Cancer. 2013; 23 (PMID: 24172097): 1603-1611https://doi.org/10.1097/IGC.0b013e3182a80ac8
        View in Article
        • Powell C.B.
        • Chen L.
        • McLennan J.
        • et al.
        Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers. Experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
        Int. J. Gynecol. Cancer. 2011; 21 (PMID: 21670699): 846-851https://doi.org/10.1097/IGC.0b013e31821bc7e3
        View in Article
        • Cass I.
        • Walts A.
        • Karlan B.Y.
        Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?.
        Gynecol. Oncol. 2010; 117 (PMID: 20110118): 27-31https://doi.org/10.1016/j.ygyno.2009.12.023
        View in Article
        • Shu C.A.
        • Pike M.C.
        • Jotwani A.R.
        • et al.
        Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations.
        JAMA Oncol. 2016; (Epub ahead of print PMID: 27367496)https://doi.org/10.1001/jamaoncol.2016.1820
        View in Article

      8. G Landon, J Stewart, M Deavers, et al. Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: A 10-year experience and reappraisal of its clinical utility. DOI: http://dx.doi.org/10.1016/j.ygyno.2005.12.021, (PMID: 16430946).

        View in Article
        • Prat J.
        • Olawaiye A.B.
        • Bermudez A.
        • et al.
        Amin M.B. Edge S. Greene F.L. Ovary, Fallopian tube, and Primary Peritoneal Carcinomas. AJCC Cancer Staging Manual. 8th edition. Springer International Publishing, 2017
        View in Article
        • Powell C.B.
        • Swisher E.M.
        • Cass I.
        • et al.
        Long term follow-up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk-reducing salpingo-oophorectomy.
        Gynecol. Oncol. 2013; 129 (PMID: 23391663): 364-371https://doi.org/10.1016/j.ygyno.2013.01.029
        View in Article

      11. Genetic/Familial High Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2017.

        View in Article

      Article info

      Identification

      DOI: https://doi.org/10.1016/j.ygyno.2016.10.007

      Copyright

      © 2016 Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX